Delcath slips on FDA delay for drug/device Melblez Kit
This article was originally published in Scrip
Shares of Delcath Systems took a 6.8% hit on 8 April after the US FDA delayed by three months the Prescription Drug User Fee Act (PDUFA) action date for the company's new drug application (NDA) Melblez Kit (melphalan), a drug/device injectable combination treatment for patients with unresectable ocular melanoma metastatic to the liver.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.